DE3684546D1 - Herstellung mit hoher leistung des aktivfaktors ix. - Google Patents

Herstellung mit hoher leistung des aktivfaktors ix.

Info

Publication number
DE3684546D1
DE3684546D1 DE8686902988T DE3684546T DE3684546D1 DE 3684546 D1 DE3684546 D1 DE 3684546D1 DE 8686902988 T DE8686902988 T DE 8686902988T DE 3684546 T DE3684546 T DE 3684546T DE 3684546 D1 DE3684546 D1 DE 3684546D1
Authority
DE
Germany
Prior art keywords
pct
manufacture
active factor
high performance
date
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE8686902988T
Other languages
English (en)
Inventor
Randal J Kaufman
Charles B Shoemaker
Louise C Wasley
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Genetics Institute LLC
Original Assignee
Genetics Institute LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=24914546&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DE3684546(D1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Genetics Institute LLC filed Critical Genetics Institute LLC
Application granted granted Critical
Publication of DE3684546D1 publication Critical patent/DE3684546D1/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
    • C12N1/20—Bacteria; Culture media therefor
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • C12N9/6424—Serine endopeptidases (3.4.21)
    • C12N9/644—Coagulation factor IXa (3.4.21.22)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/21—Serine endopeptidases (3.4.21)
    • C12Y304/21022—Coagulation factor IXa (3.4.21.22)
DE8686902988T 1985-04-22 1986-04-17 Herstellung mit hoher leistung des aktivfaktors ix. Expired - Lifetime DE3684546D1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US72543685A 1985-04-22 1985-04-22
PCT/US1986/000817 WO1986006408A1 (en) 1985-04-22 1986-04-17 HIGH YIElD PRODUCTION OF ACTIVE FACTOR IX

Publications (1)

Publication Number Publication Date
DE3684546D1 true DE3684546D1 (de) 1992-04-30

Family

ID=24914546

Family Applications (1)

Application Number Title Priority Date Filing Date
DE8686902988T Expired - Lifetime DE3684546D1 (de) 1985-04-22 1986-04-17 Herstellung mit hoher leistung des aktivfaktors ix.

Country Status (8)

Country Link
US (1) US4770999A (de)
EP (1) EP0218713B1 (de)
JP (1) JP2584443B2 (de)
KR (1) KR880700060A (de)
AT (1) ATE74164T1 (de)
AU (1) AU5864086A (de)
DE (1) DE3684546D1 (de)
WO (1) WO1986006408A1 (de)

Families Citing this family (56)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4775624A (en) * 1985-02-08 1988-10-04 Eli Lilly And Company Vectors and compounds for expression of human protein C
US5171569A (en) * 1985-03-15 1992-12-15 National Research Development Corporation Factor IX preparations uncontaminated by plasma components or pox virus
US4959318A (en) * 1985-06-27 1990-09-25 Zymogenetics, Inc. Expression of protein C
US5516650A (en) * 1985-06-27 1996-05-14 Zymogenetics, Inc. Production of activated protein C
EP0245949B1 (de) * 1986-04-09 1997-10-29 Eli Lilly And Company Verfahren zur Anwendung von den BK-Virus-Verstärker enthaltenden eukaryotischen Expressionsvektoren
FR2599752B1 (fr) * 1986-06-10 1989-11-03 Transgene Sa Variants de l'alpha1- antitrypsine utiles notamment comme inhibiteurs de la kallikreine
FR2600334B1 (fr) * 1986-06-23 1989-05-12 Transgene Sa Vecteurs d'integration dans les cellules eucaryotes assurant l'expression du facteur ix, lignees celullaires obtenues et procede pour leur preparation
US5082774A (en) * 1988-08-30 1992-01-21 The General Hospital Corporation Recombinant human nerve growth factor
FR2638643B1 (fr) * 1988-11-09 1991-04-12 Transgene Sa Sequence d'adn codant pour le facteur ix humain ou une proteine analogue, vecteur d'expression, cellules transformees, procede de preparation du facteur ix et produits obtenus correspondants
US5047335A (en) * 1988-12-21 1991-09-10 The Regents Of The University Of Calif. Process for controlling intracellular glycosylation of proteins
US5225537A (en) * 1989-12-29 1993-07-06 Zymogenetics, Inc. Methods for producing hybrid phospholipid-binding proteins
JP3330932B2 (ja) * 1990-01-29 2002-10-07 ノボ ノルディスク ヘルス ケア アクチェンゲゼルシャフト 抗凝固剤タンパク質
WO1992009698A1 (en) * 1990-11-26 1992-06-11 Genetics Institute, Inc. Expression of pace in host cells and methods of use thereof
US5861374A (en) * 1991-02-28 1999-01-19 Novo Nordisk A/S Modified Factor VII
US5997864A (en) 1995-06-07 1999-12-07 Novo Nordisk A/S Modified factor VII
US5788965A (en) * 1991-02-28 1998-08-04 Novo Nordisk A/S Modified factor VII
US5833982A (en) 1991-02-28 1998-11-10 Zymogenetics, Inc. Modified factor VII
US5817788A (en) * 1991-02-28 1998-10-06 Zymogenetics, Inc. Modified factor VII
AU671586B2 (en) * 1991-03-01 1996-09-05 Aventis Behring Llc Preparation of factor IX
US6039944A (en) * 1992-02-28 2000-03-21 Zymogenetics, Inc. Modified Factor VII
US6372716B1 (en) 1994-04-26 2002-04-16 Genetics Institute, Inc. Formulations for factor IX
AT403167B (de) * 1994-11-14 1997-11-25 Immuno Ag Selektion und expression von fremdproteinen mittels eines selektions-amplifikations-systems
US5770700A (en) * 1996-01-25 1998-06-23 Genetics Institute, Inc. Liquid factor IX formulations
US6475725B1 (en) * 1997-06-20 2002-11-05 Baxter Aktiengesellschaft Recombinant cell clones having increased stability and methods of making and using the same
AU5471501A (en) 2000-03-22 2001-10-03 Octagene Gmbh Production of recombinant blood clotting factors in human cell lines
AU2002225681A1 (en) * 2000-11-15 2002-05-27 Globe Immune, Inc. Yeast-dentritic cell vaccines and uses thereof
US7220718B2 (en) 2001-08-03 2007-05-22 United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Oral treatment of hemophilia
EP2305311A3 (de) 2001-10-10 2011-07-20 BioGeneriX AG Glykokonjugation von Peptiden
PT2279753E (pt) 2001-10-10 2016-01-15 Novo Nordisk As Remodelação e glicoconjugação de péptidos
CA2522345A1 (en) 2003-04-09 2004-11-18 Neose Technologies, Inc. Glycopegylation methods and proteins/peptides produced by the methods
WO2006101474A1 (en) 2005-03-15 2006-09-28 University Of North Carolina At Chapel Hill Methods and compositions for producing active vitamin k-dependent proteins
JP2007506433A (ja) 2003-09-23 2007-03-22 ユニヴァーシティ・オヴ・ノース・キャロライナ・アト・チャペル・ヒル ビタミンｋエポキシド還元酵素遺伝子内の一塩基多型とワルファリン用量とを相関させるための方法および組成物
DE602005024955D1 (de) * 2004-03-19 2011-01-05 Baxter Healthcare Sa Faktor ixa zur behandlung von blutungsstörungen
AU2005260763B2 (en) 2004-06-30 2011-12-22 Nektar Therapeutics Polymer-factor IX moiety conjugates
EP1707634A1 (de) 2005-03-29 2006-10-04 Octapharma AG Verfahren zur Isolierung von rekombinant hergestellten Proteinen
EP1891231A4 (de) 2005-05-25 2011-06-22 Novo Nordisk As Glykopegylierter faktor ix
EP2385125A3 (de) 2005-12-21 2012-04-11 Inspiration Biopharmaceuticals, Inc. Verfahren zur Herstellung von Biologisch aktiven Vitamin K-abhängigen Proteinen aus rekombinanten Verfahren
EP2084274A2 (de) 2006-06-19 2009-08-05 Nautilus Technology LLC Modifizierte gerinnungsfaktor-ix-polypeptide und deren verwendung zur behandlung
US9212214B2 (en) * 2009-07-10 2015-12-15 Csl Limited Methods of increasing the expression yield of vitamin K-dependent proteins
WO2011028228A1 (en) 2009-08-24 2011-03-10 Amunix Operating Inc. Coagulation factor vii compositions and methods of making and using same
WO2011095604A1 (en) 2010-02-04 2011-08-11 Octapharma Biopharmaceuticals Gmbh Half-life prolongation of proteins
JP6055412B2 (ja) 2010-09-17 2016-12-27 バクスアルタ ゲーエムベーハー 弱酸性〜中性のｐＨにおける、ヒスチジンを有する水性製剤を介した免疫グロブリンの安定化
ES2556454T3 (es) 2010-10-05 2016-01-18 Novo Nordisk Health Care Ag Proceso para producción de proteínas
EP2655607A4 (de) 2010-12-21 2014-05-14 Univ North Carolina Verfahren und zusammensetzungen zur herstellung aktiver vitamin-k-abhängiger proteine
EP2822577B1 (de) 2012-02-15 2019-02-06 Bioverativ Therapeutics Inc. Rekombinante faktor-viii-proteine
SI3564260T1 (sl) 2012-02-15 2023-02-28 Bioverativ Therapeutics Inc. Sestavki faktorja VIII in postopki njegove izdelave in uporabe
WO2015023891A2 (en) 2013-08-14 2015-02-19 Biogen Idec Ma Inc. Factor viii-xten fusions and uses thereof
MX2018001497A (es) 2015-08-03 2018-05-15 Bioverativ Therapeutics Inc Proteinas de fusion de factor ix y metodos para producirlas y usarlas.
TN2019000164A1 (en) 2016-11-23 2020-10-05 Bioverativ Therapeutics Inc Mono- and bispecific antibodies binding to coagulation factor ix and coagulation factor x
IL266972B2 (en) 2016-12-02 2024-04-01 Bioverativ Therapeutics Inc Methods for the treatment of hemophilic arthritis with the help of chimeric blood coagulation factors
AR110871A1 (es) 2017-01-31 2019-05-08 Bioverativ Therapeutics Inc Proteínas de fusión de factor ix y métodos de fabricación y uso de las mismas
JP7209298B2 (ja) 2017-03-31 2023-01-20 公立大学法人奈良県立医科大学 血液凝固第ｖｉｉｉ因子の機能を代替する多重特異性抗原結合分子を含有する、血液凝固第ｉｘ因子異常症の予防および／または治療に用いられる医薬組成物
JP7261739B2 (ja) 2017-04-27 2023-04-20 中外製薬株式会社 薬物動態が改善された血液凝固第ｉｘ因子
WO2019032898A1 (en) 2017-08-09 2019-02-14 Bioverativ Therapeutics Inc. NUCLEIC ACID MOLECULES AND USES THEREOF
KR20210042128A (ko) 2018-08-09 2021-04-16 바이오버라티브 테라퓨틱스 인크. 핵산 분자 및 비바이러스 유전자 치료를 위한 이의 용도
CA3116331A1 (en) 2018-10-18 2020-04-23 Intellia Therapeutics, Inc. Compositions and methods for expressing factor ix

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3380848D1 (en) * 1982-08-04 1989-12-21 Nat Res Dev Molecular cloning of the gene for human anti-haemophilic factor ix
GB2125409B (en) * 1982-08-04 1985-11-13 Nat Res Dev Genetic engineering
FR2564106B1 (fr) * 1984-05-09 1988-04-22 Transgene Sa Vecteurs d'expression du facteur ix, cellules transformees par ces vecteurs et procede de preparation du facteur ix.
WO1985005376A1 (fr) * 1984-05-22 1985-12-05 Transgene S.A. Vecteurs d'expression du facteur ix et lignees cellulaires produisant le facteur ix actif
US4775624A (en) * 1985-02-08 1988-10-04 Eli Lilly And Company Vectors and compounds for expression of human protein C
DE3684947D1 (de) * 1985-03-15 1992-05-27 Nat Res Dev Faktor-ix-protein.
GR860984B (en) * 1985-04-17 1986-08-18 Zymogenetics Inc Expression of factor vii and ix activities in mammalian cells

Also Published As

Publication number Publication date
EP0218713A4 (de) 1987-04-28
WO1986006408A1 (en) 1986-11-06
JP2584443B2 (ja) 1997-02-26
JPS62502514A (ja) 1987-10-01
EP0218713B1 (de) 1992-03-25
KR880700060A (ko) 1988-02-15
EP0218713A1 (de) 1987-04-22
US4770999A (en) 1988-09-13
AU5864086A (en) 1986-11-18
ATE74164T1 (de) 1992-04-15

Similar Documents

Publication Publication Date Title
DE3684546D1 (de) Herstellung mit hoher leistung des aktivfaktors ix.
DE59803845D1 (de) Sulfinsäurederivate und deren herstellung und verwendung
DE69231947D1 (de) Genherstellung zur produktion von transgenfisch
DK0554343T3 (da) Liposomer af kurvand stabiliseret i en DNA-gel
ES2002254T3 (es) Nuevos 5-alcoxi-2,4-diamino-alquilbenzenos asi como tintes para el cabello con 5-alcoxi-2,4-diamino-alquil-benzenos.
FI861506A (fi) Foerfarande foer framstaellning av 1,2-ditiolan-3-pentansyra (tioktsyra).
DE59208974D1 (de) Neue pyrazinderivative, ihre herstellung und verwendung
ES2191343T3 (es) Derivado de ribonucleoxido y su procedimiento de preparacion.
DK113183D0 (da) Kroneetherforbindelser, deres fremstilling og anvendelse
DE3579955D1 (de) Verwendung von hydroxyindolderivaten zur herstellung eines arzneimittels zur senkung des blutdrucks.
DK67384D0 (da) N-iminopyridiniumbetainderivater
SE427288B (sv) Elektrolyscell av trekammartyp for elektrolys av en alkalemetallhalogenidlosning
ES2072296T3 (es) Metodo para preparar 2-fenilbenzotriazoles.
ES2040226T3 (es) Procedimiento para preparar nuevos tetrahidro-benzotiazoles.
ATE26258T1 (de) Herstellung von phenylalaninen durch hydrierung von phenylserinen.
FI870460A0 (fi) Foerfarande foer framstaellning av nya terapeutiskt anvaendbara 5-substituerade oktahydroindolizinderivat och vid foerfarandet anvaendbara mellanprodukter.
ATE73792T1 (de) Annaeherung zur herstellung von natuerlicher vitamin e verwendender asymetrischer synthese.
KR860003828A (ko) 맥반의왕석을 함유하는 세안용 조성물
DK61785D0 (da) 2-alkoxyaminosulfonylbenzensulfonylurinstofderivater, deres fremstilling og anvendelse som herbicider
DE3766282D1 (de) Herstellung von trichlorphenol.
ES8706202A1 (es) Procedimiento para la obtencion de efomicinas a,b.c.d y f.
FR2432540A1 (fr) Colorants reactifs
SU823606A1 (ru) Турбоагрегат
DE3668166D1 (de) Verfahren zur herstellung von alkylarylethern.
FR2423519A1 (fr) Colorants reactifs

Legal Events

Date Code Title Description
8363 Opposition against the patent
8327 Change in the person/name/address of the patent owner

Owner name: GENETICS INSTITUTE, LLC, CAMBRIDGE, MASS., US